Table 2.

SNA histochemistry, clinic-histopathologic features and immunohistochemistry in IDC

SNA (n=225)
	Negative (n=150)	%	Positive (n=75)	%	P
Age (years)
<50	64	42.7	28	37.3	0.267a
>50	86	57.3	47	62.7
Menstrual Status
Pre-menopausal	57	38.0	21	28.0	0.090a
Post-menopausal	93	62.0	54	72.0
Size (mm)
<20	44	29.3	24	32.0	0.794b
20-50	61	40.7	27	36.0
>50	45	30.0	24	32.0
Metastasis					0.064a
No	114	76.0	49	65.3
Yes	36	24.0	26	34.7
Death					0.011a
No	112	74.7	44	58.7
Yes	38	25.3	31	41.3
Recurrence
No	132	88.0	64	85.3	0.357a
Yes	18	12.0	11	14.7
Tumor Grade
I	53	35.3	29	38.7	0.775b
II	72	48.0	36	48.0
III	25	16.7	10	13.3
Lymph node Status
Negative	80	53.3	28	37.3	0.017a
Positive	70	46.7	47	62.7
Tumor Stage
I	21	14.0	11	14.7	0.932b
II	69	46.0	33	44.0
III	53	35.3	26	34.7
IV	7	4.7	5	6.7
Estrogen Receptor
Negative	56	37.3	20	26.7	0.073a
Positive	94	62.7	55	73.3
Progesterone Receptor
Negative	65	43.3	22	29.3	0.029a
Positive	85	56.7	53	70.7
Ki-67
Negative	89	59.3	54	72.0	0.042a
Positive	61	40.7	21	28.0
p53
Negative	55	36.7	21	28.0	0.125a
Positive	95	63.3	54	72.0
HER-2
Negative	121	80.7	57	76.0	0.260a
Positive	29	19.3	18	24.0
MUC1
Negative	103	68.7	36	48.0	0.002a
Positive	47	31.3	39	52.0

^aFisher’s exact test;

^b X² test.